Boothbay Fund Management’s Soleno Therapeutics SLNO Stock Holding History

Boothbay Fund Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,700	Closed	-$820K	–	2445
2025 Q4	$820K	Sell	17,700 -36,100	-67%	-$1.98M	0.01%	883
2025 Q3	$3.64M	Sell	53,800 -39,600	-42%	-$2.94M	0.05%	410
2025 Q2	$7.83M	Buy	93,400 +52,100	+126%	+$3.9M	0.15%	181
2025 Q1	$2.95M	Buy	41,300 +19,700	+91%	+$959K	0.08%	342
2024 Q4	$971K	Buy	+21,600	New	+$1.12M	0.02%	648
2024 Q3	–	Sell	-15,900	Closed	-$649K	–	1903
2024 Q2	$649K	Buy	+15,900	New	+$674K	0.02%	904
2020 Q3	–	Sell	-99	Closed	-$329K	–	1200
2020 Q2	$329K	Buy	+99	New	+$4.29K	0.02%	677

Boothbay Fund Management's SLNO Position: Q2 2026 in Review

Boothbay Fund Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 124,519 shares — an estimated $4.17M sold.

Boothbay Fund Management first reported a position in SLNO in Q2 2020 and held it in 17 quarters. The position peaked at $5.65M in Q1 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Boothbay Fund Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 124,519 Soleno Therapeutics shares in Q2 2026, an estimated $4.17M.
Boothbay Fund Management first reported a position in Soleno Therapeutics in Q2 2020 and held it in 17 quarters.
Boothbay Fund Management's Soleno Therapeutics position peaked at $5.65M in Q1 2024.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.